Home | Welcome to Contract Pharma   
Last Updated Saturday, December 20 2014

Print RSS Feed

Pluristem Completes New Manufacturing Facility



Published December 28, 2012
Related Searches: Validation Sterile Clinical Trials Manufacturing
Pluristem Therapeutics, Inc. has initiated the final validation steps for its new manufacturing facility, including the validation of several installation systems such as heating, ventilation and air conditioning (HVAC), water, oil free air and sterile room systems.
 
Zami Aberman, chairman and chief executive officer of Pluristem, said, "I am extremely proud of our team in meeting milestones for the completion of the world's first commercial cell therapy manufacturing facility. Assuming the PLX cells product candidates are successfully developed and approved by the regulators, we believe that the new facility would have the capacity to produce PLX cells for the treatment of over 150,000 patients annually estimated by Pluristem at $1 billion in production value. Additionally, as clinical trials are approved by regulators for additional indications, our new facility will enable us to supply PLX cells to conduct these trials in parallel."
 


blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On